Invited Commentary
Ductal carcinoma in situ (DCIS) is considered to be a noninvasive, nonobligate precursor lesion that demonstrates a wide variability in its ability to progress to invasive disease. Studies report that 13% to 50% of DCIS cases will progress to invasive ductal carcinoma.1-4 Despite its frequency and extensively studied nature, DCIS remains a process surrounded by controversy and unknowns, the most striking of which is the lack of id entifiable, reliable markers that predict disease progression. Oseni and colleagues certainly use their current work to highlight yet another unknown as it relates to the correlation of race and ethnicity with the incidence of this disease in the US.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Jennifer LaFemina Tags: New England surgical society article Source Type: research
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Study | Surgery